An Open-label Study to Assess the Safety and Tolerability of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in 396443-CS2 or 396443-CS10
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 08 Oct 2016 Exploratory efficacy and safety data from this trial were presented at the 2016 World Muscle Society Congress, according to a Biogen media release.
- 22 Jun 2015 Updated results in 30 children who were previously enrolled in 396443-CS2 (CTP 224879), published in the Media Release.